A Randomized, Double-Blind, Placebo-controlled, Ascending, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Mild Atopic Asthma
Phase of Trial: Phase I
Latest Information Update: 16 Dec 2016
Price : $35 *
At a glance
- Drugs RG 6149 (Primary) ; RG 6149 (Primary)
- Indications Asthma
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Amgen
- 13 Dec 2016 Status changed from active, no longer recruiting to completed.
- 04 May 2016 Planned End Date changed from 1 Apr 2016 to 1 Jun 2016.
- 04 May 2016 Status changed from recruiting to active, no longer recruiting.